Navigation Links
Genetic Engineering & Biotechnology News reports on clinical trials in developing countries
Date:3/18/2008

New Rochelle, NY, March 18, 2008Biotechnology companies are increasingly turning to developing nations as sites for clinical trials, reports Genetic Engineering and Biotechnology News (GEN). Increasing competition for clinical trial patients in the industrialized world is one of the major reasons for the offshore move, according to an article in the March 15 issue of GEN (http://www.genengnews.com/articles/chitem.aspx?aid=2401)

A ready supply of patients and large potential markets are other key drivers for the decision to conduct clinical trials in developing countries, notes John Sterling, Editor-in-Chief of GEN.

Developing nations also offer less competition from other ongoing clinical trials and patients and investigators are often eager to participate. In addition, biotech and pharma companies usually conduct trials in cities, as opposed to rural areas, since many developing world cities have doctors, staff, and equipment similar to conditions that are found in the West.

Nevertheless, there are cultural issues that must be addressed in some developing nations. For example, companies need to ascertain that the disease to be studied in a trial is actually recognized as a local morbidity. In many countries, mental illness, insomnia, and depression are seen as character weaknesses rather than as illnesses.

In the GEN article, insights on conducting clinical trials in developing countries are provided by Peregrine Pharmaceuticals, Integrated Clinical Trials Services, PharmaNet, Advaxis, and Pharm-Olam International.


'/>"/>

Contact: John Sterling
jsterling@genengnews.com
Mary Ann Liebert, Inc./Genetic Engineering News
Source:Eurekalert

Page: 1

Related medicine news :

1. Genetic Medicine Making Inroads Against Disease
2. Family communication impacts attitude about genetic counseling/testing for breast cancer
3. Genetic counselors turn to unconventional counseling to meet demand for genetic testing
4. GSK Data Suggests Efficacy of Advair(R) and Serevent(R) is Not Impacted by Genetic Profile
5. DNA detectives find genetic markers for lung cancers most likely to recur
6. Genetic Markers May Predict Lung Cancer Recurrence
7. Genetic analysis reveals range of Rett syndrome
8. Genetic research unveils common origins for distinct clinical diagnoses
9. New stem cell technique improves genetic alteration
10. Einstein researchers genetically engineer immune cells into potent weapons for battling HIV
11. Genetic Test Predicts Response to Warfarin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2017)... ... April 29, 2017 , ... TransDark is a set ... one video to the next without having to set a single keyframe in ... to enhance your video production. , TransDark features dynamic transitions that momentarily splits the ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... An April 24th article on ... stunning 180 pounds with the help of a weight loss surgery. The woman, declaring “I ... skin that have been left following her dramatic weight loss. Dr. Feiz & Associates notes ...
(Date:4/28/2017)... , ... April 28, 2017 , ... Beginning in 2017, ... their formulas. This begins with the popular ClearLungs Extra Strength formula. To ensure that ... the formula in the following ways:, , Removal of the ...
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America ... lamps offer an instant energy-saving solution for F32T8 fluorescent lamps on most instant-start ... ballasts. These 50,000 hour rated lamps utilize the existing electronic ballast, saving labor ...
(Date:4/28/2017)... ... April 28, 2017 , ... From ... College of Urgent Care Medicine will host industry leaders for the annual spring ... help those in the industry adapt to the issues currently affecting urgent care ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 20, 2017  Cogentix Medical, Inc. (NASDAQ: CGNT), ... the Urology, Uro/Gyn and Gynecology markets with innovative ... has joined the Company as Senior Vice President, ... position, Mr. Keswani will report directly to ... "Our organization is delighted that Ash has joined ...
(Date:4/20/2017)... , April 20, 2017  RXi Pharmaceuticals Corporation ... therapeutics that address significant unmet medical needs, today ... the Company,s consumer product development program, based on ... Society for Investigative Dermatology (SID) 76 th ... and promote the sciences relevant to skin health ...
(Date:4/20/2017)... , April 20, 2017  AbbVie (NYSE: ... 99 percent (n=145/146) of chronic hepatitis C virus ... 5 or 6 and compensated cirrhosis (Child-Pugh A) ... (SVR 12 ) with its investigational, pan-genotypic regimen ... rates were seen following 12 weeks of G/P ...
Breaking Medicine Technology: